2010 AnnuAl REpoRT - Ciberdem

Solvay, SA: 2008-2010
Principal Investigator: R Simó
Associate investigators: C Hernández, M García Ramírez,
M Villarroel, L Corraliza
Scientific collaborations within CIBERDEM
Identification of neurodegenerative mechanisms that
promote the development of diabetic retinopathy: the role
of insulin signalling and apoptosis
NEURONET-DIAB: 2009-2010
Coordinator: Deborah Burks
CIBERDEM groups: R Simó, D Burks, A Martínez Valverde
Glycogen-induced dysfunctions in the pancreas and retina
and their involvement in the ethiogenesis of diabetes
mellitus
GIDIPRED: 2009-2010
Coordinator: Joan J Guinovart
CIBERDEM groups: R Simó, R Gomis, JJ Guinovart
Adult adipose tissue-derived progenitor cells: the influence
of the clinical phenotype and adipose depot origin on their
biological properties
STEMOB: 2009-2010
Coordinator: Joan J Vendrell
CIBERDEM groups: R Simó, J Vendrell, A Zorzano,
J Balsinde, AM Gómez Foix, E Montanya, S Fernández
Veledo, M Vázquez Carrera
DEFEND-2: Durable-Response Therapy Evaluation for
Early- or New-Onset Type 1 Diabetes. TRX4_DM_007_
EU_08. Phase III
Constella Group SA: 2010-2012
Name of the participants: C Hernández (researcher), R
Simó (coordinator)
A 26-week, multinational, multi-centre, open-labelled, twoarm,
parallel, randomised, treat-to-target, efficacy and
safety comprisons of soluble insulin analogue combination
(SIAC) once daily (OD) and insulin glargine OD both in
combination with metformin in insulin-naïve subjects with
type 2 diabetes inadequately controlled on oral antidiabetic
drugs (OADs). NN5401-3590. Phase III
Novo Nordisk SA: 2009-2010
Name of the participants: A Lecube (researcher), R Simó
(coordinator)
Estudio de extension de 26 semanas, multinacional,
multicéntrico, abierto, de dos grupos paralelos y con ajuste
de dosis para comparar la eficacia y seguridad de una
combinación de un análogo soluble de insulina (SIAC)
administrado una vez al día (OD) frente a insulina glargina
(OD), ambas en combinación con metformina, en sujetos
con Diabetes tipo 2. NN5401-3726. Phase III
Novo Nordisk SA: 2010-2011
Determinants of insulin resistance and glucose tolerance
disorders, including diabetes, in severe obesity and their
changes after bariatric surgery-induced weight loss
DIASOBS: 2009-2010
Coordinator: Héctor F Escobar Morreale
CIBERDEM groups: R Simó, X Correig, E Montanya,
HF Escobar Morreale, J Vendrell
Clinical trials
Estudio multicéntrico, de 24 semanas seguido por
una extensión, aleatorizado, doble ciego controlado
con placebo y de grupos paralelos, para evaluar
la eficacia y seguridad de AVE0010 añadido a
metformina en pacientes con diabetes tipo 2 no
controlados adecuadamente con metformina.
EFC6014. Phase III
Sanofi-Aventis: 2008-2010
Name of the participants: R Simó, J Mesa and A Lecube
(researchers)
DEFEND-1: Durable-Response Therapy Evaluation for
Early- or New-Onset Type 1 Diabetes. TRX4_DM_007_
EU_08. Phase III
Constella Group SA: 2009-2011
Name of the participants: C Hernández (researcher), R
Simó (coordinator)
Immunohistochemistry of ARPE-19 cell monolayer. Tight junction
protein ZO-1 appears in red and F-actin network of the cytoskeleton
in green. Nuclei were stained with DAPI (blue). Bar: 20 µm.
2010 Annual Report
79